Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anisbel Hornia Silva

General Practice South Gate, CA Nurse Practitioner

NPI 1740763036 CMS profile 7138651

4149 Tweedy Blvd, South Gate, CA 90280

Open in the dashboard

General payments

$3,623

176 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anisbel Hornia Silva of South Gate, CA is reported in the CMS Open Payments database as having received $3,623 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,389 125
2024 General $741 31
2023 General $267 9
2022 General $165 8
2021 General $61 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anisbel Hornia Silva
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Anisbel Hornia Silva were reported at $2,389. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Anisbel Hornia Silva General Practice median Middle half National median
2019 $0 $107 $37–$285 $163
2020 $0 $75 $25–$213 $114
2021 $61 $93 $30–$272 $132
2022 $165 $103 $36–$279 $149
2023 $267 $106 $34–$276 $160
2024 $741 $114 $39–$290 $164
2025 $2,389 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $527 28 payments
  2. Alkermes, Inc. $484 26 payments
  3. AbbVie, Inc. $411 26 payments
  4. Axsome Therapeutics, Inc. $325 12 payments
  5. ITI, Inc. $303 15 payments
  6. Neurocrine Biosciences, Inc. $234 8 payments
  7. Teva Pharmaceuticals USA, Inc. $221 13 payments
  8. Novo Nordisk Inc $213 7 payments
  9. E.R. Squibb & Sons, L.L.C. $186 5 payments
  10. Vanda Pharmaceuticals Inc. $153 7 payments
  11. Other $568 29 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,588 173 payments
  2. Education $35 3 payments
Products named General payments · program years 2021–2025
  1. LYBALVI $484 26 payments
  2. REXULTI $482 22 payments
  3. ARISTADA Cns $452 25 payments
  4. ARISTADA Cns $452 25 payments
  5. ARISTADA Cns $452 25 payments
  6. ARISTADA Cns $452 25 payments
  7. Auvelity $325 12 payments
  8. VRAYLAR $286 21 payments
  9. INGREZZA $234 8 payments
  10. Austedo XR $208 12 payments
  11. Other $1,820 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 105 drugs

Part D claims

4,909

Median for Nurse Practitioner: 389

Drug cost

$434,300

Median for Nurse Practitioner: $21,885

Branded share of claims

21%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 48 $74,687
Jardiance Empagliflozin Brand 80 $66,039
Ozempic Semaglutide Brand 56 $55,130
Januvia Sitagliptin Phosphate Brand 52 $34,171
Rexulti Brexpiprazole Brand 16 $25,546
Tresiba Flextouch U-200 Insulin Degludec Brand 32 $19,108
Entresto Sacubitril/Valsartan Brand 20 $18,433
Diclofenac Sodium Generic 103 $14,320
Eliquis Apixaban Brand 13 $13,891
Mounjaro Tirzepatide Brand 12 $13,527

The 10 drugs with the highest cost, of 105 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$20,411

Of which drugs: $165

Medicare patients

92

Average age 69

Services billed

729

54 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Depression 45%
Arthritis 45%
Chronic kidney disease 33%
Heart failure 28%
Ischemic heart disease 26%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 26 $26
Injection, ketorolac tromethamine, per 15 mg J1885 Office 15 52 $20
Injection, ceftriaxone sodium, per 250 mg J0696 Office 12 48 $12
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 14 98 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COBENFY
  • E.R. Squibb & Sons, L.L.C. $124
$124 — —
ARISTADA
  • Alkermes, Inc. $122
$122 — —
CAPLYTA
  • ITI, Inc. $99
$99 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $43
  • Lundbeck LLC $35
$78 16 —
INGREZZA
  • Neurocrine Biosciences, Inc. $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record